BPH: Why Do Patients Fail Medical Therapy?
Purpose of Review
In this article, we review why patients may fail medical therapy for benign prostatic hyperplasia (BPH) and by doing so, gain a better understanding of the disease process and how to optimize the care of these patients.
A growing body of literature has attempted to better characterize the various mechanisms by which patients develop BPH as well as identify predictors of disease progression and treatment failure.
BPH is a heterogenous disease process. A more personalized approach to treatment, including patient selection for medical or surgical management, would allow us to optimize patient care.
KeywordsBenign prostatic hyperplasia Medical therapy Alpha-blockers 5alpha-reductase inhibitors Predictors of treatment failure Clinical trial results
Compliance with Ethical Standards
Conflict of Interest
Zeynep G. Gul and Steven A. Kaplan each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255–63. https://doi.org/10.1111/j.1464-410X.1976.tb10214.x.CrossRefGoogle Scholar
- 5.Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148(5):1467–74. https://doi.org/10.1016/S0022-5347(17)36941-0.CrossRefPubMedGoogle Scholar
- 7.Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004.Google Scholar
- 12.Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996. doi: https://doi.org/10.1056/NEJM199608223350801, 335, 533, 540.CrossRefGoogle Scholar
- 13.Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119–26. https://doi.org/10.1016/S0090-4295(02)02114-3.CrossRefPubMedGoogle Scholar
- 16.Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40. https://doi.org/10.1016/j.juro.2009.02.034.CrossRefPubMedGoogle Scholar
- 17.Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108:388–94. https://doi.org/10.1111/j.1464-410X.2011.10195.x.CrossRefPubMedGoogle Scholar
- 19.Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66:1052–5. https://doi.org/10.1111/j.1742-1241.2012.03010.x.CrossRefPubMedGoogle Scholar
- 20.• Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177:683–91. https://doi.org/10.1001/jamainternmed.2017.0089. This large, matched cohort study raises awareness that depression may be a possible and until recently unknown side effect of 5ARIs. The results call into question our current practice patterns. CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Tae BS, Jeon JJ, Choi H, Cheon J, Park JY, Base JH. Alpha-blocker and risk of dementia in patients with benign prostate hyperplasia: a nationwide population-based study using the National Health Insurance Service database. J Urol. 2019.Google Scholar
- 26.McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071–7. https://doi.org/10.1016/j.juro.2006.10.055.CrossRefPubMedGoogle Scholar
- 27.Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236–44. https://doi.org/10.1016/j.eururo.2008.01.075.CrossRefPubMedGoogle Scholar
- 28.Brock GB, McVary KT, Roehrborn CG, et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol. 2014;191:405–11. https://doi.org/10.1016/j.juro.2013.09.057.CrossRefPubMedGoogle Scholar
- 29.Gravas S, T. Bach AB, M. Drake, M. Gacci.2016 Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). In: European Association of Urology 2016. doi: https://doi.org/10.1017/CBO9781107415324.004.
- 30.Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. J Am Med Assoc. 2006;296:2319–28. https://doi.org/10.1001/jama.296.19.2319.CrossRefGoogle Scholar
- 31.McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98. https://doi.org/10.1056/NEJMoa030656.CrossRefPubMedGoogle Scholar
- 32.Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217–20. https://doi.org/10.1016/S0022-5347(05)00041-8.CrossRefPubMedGoogle Scholar
- 33.Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31. https://doi.org/10.1016/j.eururo.2009.09.035.CrossRefPubMedGoogle Scholar
- 34.Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003;44:539–45. https://doi.org/10.1016/S0302-2838(03)00376-2.CrossRefPubMedGoogle Scholar
- 36.Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418–25. https://doi.org/10.1016/j.eururo.2014.11.006.CrossRefPubMedGoogle Scholar
- 38.Kojima Y, Sasaki S, Kubota Y, Hayase M, Hayashi Y, Shinoura H, et al. Expression of α1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective α1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol. 2008;179:1040–6. https://doi.org/10.1016/j.juro.2007.10.082.CrossRefPubMedGoogle Scholar
- 39.Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, et al. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011. https://doi.org/10.1002/pros.21348.
- 40.Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, et al. Age and obesity promote methylation and suppression of 5α-reductase 2: implications for personalized therapy of benign prostatic hyperplasia. J Urol. 2015;194:1031–7. https://doi.org/10.1016/j.juro.2015.04.079.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Kang PM, Kim YJ, Seo WT, et al. Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia. World J Urol. 2018.Google Scholar
- 42.Gu X, Na R, Huang T, Wang L, Tao S, Tian L, et al. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. J Urol. 2013;190:615–9. https://doi.org/10.1016/j.juro.2013.03.024.CrossRefPubMedGoogle Scholar
- 45.Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011. https://doi.org/10.3909/riu0535.
- 47.• Albisinni S, Biaou I, Marcelis Q, Aoun F, De Nunzio C, Roumeguère T. New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol. 2016;16:58. https://doi.org/10.1186/s12894-016-0176-0. An excellent review of current treatments for BPH, recent advances in our understanding BPH pathophysiology, and potential therapeutic targets. CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111:304–11. https://doi.org/10.1111/j.1464-410X.2012.11559.x.CrossRefPubMedGoogle Scholar
- 55.Torkko KC, Wilson RS, Smith EE, Kusek JW, Van Bokhoven A, Lucia MS. Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J Urol. 2015;194:454–61. https://doi.org/10.1016/j.juro.2015.03.103.CrossRefPubMedGoogle Scholar
- 57.• Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol. 2016. https://doi.org/10.1016/j.juro.2016.06.090 One of the largest studies, with long-term follow-up, that evaluates the association between prostatic inflammation and LUTS and confirms the relevance of inflammation as a potential therapeutic target. CrossRefGoogle Scholar
- 60.Hirayama K, Masui K, Hamada A, Shichiri Y, Masuzawa N, Hamada S. Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology. 2015;86:565–9. https://doi.org/10.1016/j.urology.2015.05.021.CrossRefPubMedGoogle Scholar
- 61.• Kalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MBC, et al. Intravesical prostatic protrusion: a potential marker of alpha-blocker treatment success in patients with benign prostatic enlargement. Urology. 2016. https://doi.org/10.1016/j.urology.2015.11.029 Demonstrates that IPP is negatively associated with improvements in IPPS scores after taking alpha-blockers. We believe that patients with significant IPP are likely to benefit more from surgery than medical management. CrossRefGoogle Scholar